日本語 >>
TOP page
Journal
Presentation
（Last updated : 2024-10-29 09:13:02）
Ken Nishino
Department
Kawasaki Medical School Kawasaki Medical School, Department of General Internal Medicine 2,
Position
Assistant Professor
■
Journal
1.
2023/09/01
Lean nonalcoholic fatty liver disease: Age-dependent differences in pathology, prognosis, and liver-related events
2.
2023/08/12
Brain activity in response to food images in patients with irritable bowel syndrome and functional dyspepsia
3.
2023/05/10
Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
4.
2022/04/12
Efficacy of primary drainage by endoscopic ultrasound-guided biliary drainage for unresectable pancreatic adenocarcinoma
5.
2022/03
Afferent-Loop Syndrome Treated with Endoscopic Ultrasound-Guided Drainage of the Afferent Loop with a Plastic Stent
6.
2022/01
Edematous wall thickening of the gallbladder induced by hyperthyroidism
7.
2022
Portal Hypertensive Gastropathy in Liver Cirrhosis: Prevalence, Natural History, and Risk Factors
8.
2021/11/21
Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
9.
2021/05/27
Combination of type Ⅳ collagen 7S, albumin concentration, and platelet count predicts prognosis of non-alcoholic fatty liver disease
10.
2021/05/01
Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years.
11.
2021/04/01
Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis-A Case Suggesting the "Gastrin Link Theory".
12.
2021
A Case of Successful Colon Stenting for Abscess due to Gallbladder Colon Fistula Caused by Gallbladder Cancer
13.
2020/09/04
Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals:A Cross-Sectional Study
14.
2020
Efficacy and safety of temporary biliary stent for prevention of post-ERCP cholangitis after endoscopic common bile duct stone removal :a retrospective study
15.
2019/10/15
High Prevalence of Autoimmune Gastritis in Patients with Nonalcoholic Steatohepatitis
16.
2018/06
Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
17.
2018/06
Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
18.
2018/02
Prevalence of pruritus in patients with chronic liver disease: A multicenter study.
19.
2017/10
Effective Biomarkers for advance fibrosis NASH and reflect biomarkers as changes of liver fibrosis with NASH
20.
2017/10
Prediction of hepatocellular carcinoma following direct-acting antiviral treatment for chronic hepatitis C
21.
2017/10
Sequential PEG-IFNa-2a and TDF+PEG-IFNa-2a combination therapy after long-term nucleic acid analog treatment effectively reduce hepatitis B surface antigten levels
22.
2017/04
Case report of diet-related improvements of non-alcoholic steatohepatitis evaluated by four consecutive liver biopsies
23.
2016/11
The association with non-alcoholic steatohepatitis and autoimmune gastritis-Coincidence or true nature?
24.
2016/10
Elevated WFAM2BP, ALT flare and HBs decline>1.0Log/ml during Peg IFN were predict drug free and HBs antigen clearance in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients
25.
2016/10
The level of the macrophage activation marker soluble CD163 is apredictor of fibrosis progression and inflammation in non-alcoholic steatohepatitis(NASH)
26.
2016/10
The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic response with chronic hepatitis C patients
27.
2016/06
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey
28.
2015/10
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease:multicenter survey
29.
2015/04
Non-occlusive mesenteric ischemia after splenic metastasectomy for small-cell lung cancer
30.
2015
Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease
31.
2015
Elevated Serum Levels of M2BPGI Predict the Burned Out NASH and Hepatocellular Carcinoma with Non-Alcoholic Steatohepatitis
32.
2015
Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
33.
2014/11
Effect of achieving drug-free status and HBs antigen decline in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients.
34.
2014/11
WFA-M2BP levels are usefull indicators of progression and improvement for monitoring liver fibrosis in patients with nonalcoholic steatohepatitis/ nonalcoholic fatty liver disease.
35.
2014/03
Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy.
36.
2013/03
Treatment of nonalcoholic steatohepatitis with vitamins E and C:a pilot study
37.
2012/09
A prospective study showing poor prognosis in Japanese NASH patients with fibrosis stage F3-4
38.
2009/07
Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis.
Display 5 items
Display all(38)
■
Presentation
1.
2023/09/07
Lean nonalcoholic steatotic liver disease: Age-dependent differences in pathology, prognosis, and liver-related events （Poster notice）
2.
2018/11/09
Combination of shear-wave elastography and liver fibrosis markers predicts severe fibrosis in patients with non-alcoholic steatohepatitis （Poster notice，Panelist at Symposium/Workshop (Applied)）
3.
2018/09/07
Effective biomarkers for advance fibrosis NASH and reflect biomarkers as changes of liver fibrosis with NASH （Poster notice，Panelist at Symposium/Workshop (Applied)）
4.
2018/06/02
EVALUATION OF THE PRECUTTING TECHNIQUES FOR DIFFICULT BILIARY CANNULATION TO A MAJOR PAPILLA AROUND A DIVERTICLE （Speech，General）
5.
2018/06/02
「EVALUATION OF THE PRECUTTING TECHNIQUES FOR DIFFICULT BILIARY CANNULATION TO A MAJOR PAPILLA AROUND A DIVERTICLE」 （Poster notice，General）
6.
2017/11/01
METACHRONOUS DEPLOYMENT OF FOUR PLASTIC AND FOUR METALLIC STENTS IN THE PATIENT WITH HILAR BILE DUCT CARCINOMA SUCCESSFULLY ACHIEVED ONLY VIA ENDOSCOPIC PROCEDURE. （Speech，General）
7.
2017/10/23
Effective Biomarkers for advance fibrosis NASH and reflect biomarkers as changes of liver fibrosis with NASH （Poster notice，General）
8.
2017/10/23
Sequential PEG-IFNa-2a and TDF+PEG-IFNa-2a combination therapy after long-term nucleic acid analog treatment effectively reduce hepatitis B surface antigten levels （Poster notice，General）
9.
2017/10/21
Prediction of hepatocellular carcinoma following direct-acting antiviral treatment for
chronic hepatitis C （Poster notice，General）
10.
2017/05/08
Endoscpic findings by Kyoto classification is useful to detect Helicobacter pylori. （Poster notice，General）
11.
2016/11/12
The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic response with chronic hepatitis C patients （Speech，General）
12.
2016/11/11
Elevated WFAM2BP, ALT flare and HBs decline>1.0Log/ml during Peg IFN were predict drug free and HBs antigen clearance in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients （Speech，General）
13.
2016/11/11
The level of the macrophage activation marker soluble CD163 is apredictor of fibrosis progression and inflammation in non-alcoholic steatohepatitis(NASH) （Speech，General）
14.
2016/11/05
The association with non-alcoholic steatohepatitis and autoimmune gastritis-Coincidence or true nature? （Speech）
15.
2016/08/05
The pancreatic duct stent prevents post-ERCP pancreatitis effectively in the patients with naive papilla （Speech，General）
16.
2016/05/24
Needle knife precutting papillotomy dose'nt seem to be a risk factor of post ERCP pancreatitis at the selective biliary deep cannulation. （Poster notice，General）
17.
2015/07/03
Elevated serum levels of M2BPGi predict the burned out NASH and Hepatocellular carcinoma with Non-alcoholic steatohepatitis （Speech，General）
18.
2015/05/28
Artificially induced pneumothorax for computed tomography fluoroscopy-guided percutaneous radiofrequency ablation of hepatocellular carcinoma. （Speech，General）
19.
2014/12/19
Artificially induced pneumothorax for computed tomography fluoroscopy-guided percutaneous radiofrequency ablation of hepatocellular carcinoma. （Poster notice，General）
20.
2014/11/11
Effect of achieving drug-free status and HBs antigen decline in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients. （Poster notice，General）
21.
2014/11/09
WFA-M2BP LEVELS ARE USEFULL INDICATORS OF PROGRESSION AND INPROVEMENT FOR MONITORING LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS/NON-ALCOHOLIC FATTY LIVER DISEASE （Poster notice，General）
22.
2014/06/07
Clinical evaluation of metallic stent for malignant gastric outlet obstruction （Speech，Panelist at Symposium/Workshop (Applied)）
23.
2013/11/02
Usefulness of Monitoring Serum Cytokeratin-18 Levels for Evaluating Long-term Prognosis in Patients with Non-alcoholic Steatohepatitis/Non-alcoholic Fatty Liver Disease. （Poster notice，General）
24.
2013/06/07
Relationship of Hepatocellular Carcinoma and Quantitative Levels of HBV-DNA/Hbsag with Long-Term Nucleotide Analogue Therapy （Poster notice，General）
25.
2012/11/10
Quantitative levels of hepatitis B virus DNA and surface antigen and risk of Hepatocellular carcinoma in chronic HBV patients with long-term Nuclotide analogue therapy. （Poster notice，General）
Display 5 items
Display all(25)
